METTL3通过在脊柱星球细胞中的A-依赖的JAK2/STAT3激活来调节骨癌疼痛
Ming Liu1, Lijun Yang1, Zhirong Yan1
1College of Clinical Medicine for Obstetrics & Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China; Department of Anaesthesiology, Fujian Maternity and Child Health Hospital, Fuzhou, China.
Cellular signalling
|August 2, 2025
概括
甲基转移酶类3 (METTL3) 通过在脊髓星球细胞中甲基化JAK2 mRNA来驱动骨癌疼痛. 抑制METTL3可降低神经炎症和疼痛,提供一种潜在的新疗法.
科学领域:
- 表观遗传学和分子生物学
- 神经科学和疼痛研究研究
背景情况:
- 由甲基转移酶类3 (METTL3) 调节的N6-甲基氨酸 (m6A) 修饰与表观遗传变化有关.
- 已知METTL3在癌症和炎症性疼痛中的作用,但其确切的机制尚不清楚.
- 骨癌疼痛 (BCP) 涉及由TNF-α和IL-1β等细胞因子调解的神经炎症.
研究的目的:
- 阐明通过METTL3-介导的甲基化促进骨癌疼痛的途径.
- 在BCP期间调查METTL3在JAK2mRNA调节中在脊髓天体细胞中的作用.
主要方法:
- 使用了一种骨癌疼痛小鼠模型.
- 在脊髓中研究了METTL3和m6A水平.
- 采用了METTL3敲击 (shRNA) 和药理学的m6A抑制 (STM2457).
- 评估了JAK2的mRNA和蛋白质表达,星球细胞激活,炎症媒介和疼痛行为 (PWMT,NSF).
主要成果:
- 随着BCP的进展,METTL3水平和m6的JAK2mRNA的修饰增加了.
- 一种抑制降低了JAK2/STAT3信号传递,天体细胞激活和炎症标志物.
- 针对METTL3的干预措施显著改善了BCP小鼠的疼痛反应.
结论:
- METTL3促进骨癌疼痛,通过促进脊髓星球细胞中JAK2mRNA的甲基化,驱动神经炎症.
- 在这个过程中,JAK2/STAT3信号通路是关键的中间体.
- 抑制METTL3是一种有前途的治疗策略,用于治疗骨癌疼痛.
相关概念视频
The JAK-STAT Signaling Pathway
9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
9.2K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
MAPK Signaling Cascades
6.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.1K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K


